Lumida
/ARVN
⌘K
Arvinas Inc

Arvinas Inc

ARVN
$8.45USD-2.99%-0.26 today

MARKET CAP

552.5M

P/E (TTM)

FWD P/E

DAY RANGE

$8 – $9

52W RANGE

$7
$15

AI Summary

Stalk
StalkMedium

ARVN is in an early Stage 1 consolidation following a terminal decline, with a Bullish Pivot Point pattern signaling failure of downside control and structural repair toward a higher equilibrium. The medium-term bias is bullish within this emerging base, but short-term conditions are extended near the upper boundary and RSI is overbought. Execution should be deferred, stalking for a pullback and absorption around the rising 9/20 EMA zone near prior resistance.

  • Q2 2026 revenue jumped to $249.7 M (+1,045% YoY) from $22.4 M a year ago
  • Diluted EPS of $2.58 in Q2 vs loss of $0.84 prior year marks profitability shift
  • Q2 profit relies on $112.5 M in Pfizer/Rigel licensing revenue with no guarantee of repeats
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$53.6M$131.4M$78.5M$263.4M$262.6M
YoY %+106.9%+145.1%-40.3%+235.5%-0.3%
P / Sales76.6x13.5x29.3x5.2x3.2x
EV / Sales89.5x18.2x33.6x6.9x3.7x
Gross Profit, Adj.$53.6M$131.4M$78.5M$263.4M$262.6M
YoY %+106.9%+145.1%-40.3%+235.5%-0.3%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit89.5x18.2x33.6x6.9x3.7x
EBITDA, Adj.$-182.0M$-255.1M$-395.4M$-241.0M$-111.2M
YoY %-56.0%-40.2%-55.0%+39.0%+53.9%
Margin %-339.6%-194.1%-503.7%-91.5%-42.3%
EV / EBITDA-26.4x-9.4x-6.7x-7.5x-8.8x
EBIT$-188.4M$-263.2M$-401.5M$-250.2M$-118.5M
YoY %-56.0%-39.7%-52.5%+37.7%+52.6%
Margin %-351.5%-200.3%-511.5%-95.0%-45.1%
EV / EBIT-25.5x-9.1x-6.6x-7.2x-8.3x
Net Income$-191.0M$-282.5M$-367.3M$-198.9M$-80.8M
YoY %-60.1%-47.9%-30.0%+45.8%+59.4%
Net Margin-356.3%-215.0%-467.9%-75.5%-30.8%
EPS (GAAP)-$3.82-$5.31-$6.62-$2.77-$1.14
YoY %-26.5%-39.0%-24.7%+58.2%+58.8%